PMA device
NMP22 BladderChek Test
Abbott Diagnostics Scarborough, Inc. · System, Test, Tumor Marker, For Detection Of Bladder Cancer (NAH, Class III) · First FDA decision Apr 25, 2003, newest Jul 12, 2022Bladder cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
0
Naming "NMP22 BladderChek"
MAUDE reports
0
Brand "NMP22 BladderChek", since 2015
PubMed studies
37
Mentioning "NMP22 BladderChek"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NMP22 BladderChek Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- NMP22 BladderChek TestPMA supplement
P940035-S017 · Decided Jul 12, 2022 · 154 days after receipt · Normal 180 Day Track No User Fee
Device type: System, test, tumor marker, for detection of bladder cancer (NAH) · Laboratory Medicine & Pathology
- NMP22 BLADDERCHEK TEST KITPMA supplement
P940035-S006 · Decided Nov 15, 2011 · 188 days after receipt · Normal 180 Day Track No User Fee
Device type: System, test, tumor marker, for detection of bladder cancer (NAH) · Laboratory Medicine & Pathology
- NMP22 BLADDERCHEK TEST KITPMA supplement
P940035-S004 · Decided May 20, 2008 · 54 days after receipt · Normal 180 Day Track No User Fee
Device type: System, test, tumor marker, for detection of bladder cancer (NAH) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38678WPS Insurance CorporationUpdated Jun 18, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38584CGS Administrators, LLCUpdated Apr 6, 2026
- Bladder/Urothelial Tumor MarkersLocal determinationIn effectL36975CGS Administrators, LLCUpdated Feb 20, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38643Noridian Healthcare Solutions, LLCUpdated Jan 26, 2026
- Lab: Bladder/Urothelial Tumor MarkersLocal determinationIn effectL36678Noridian Healthcare Solutions, LLCUpdated Oct 27, 2025
- MolDX: Phenotypic Biomarker Detection in Circulating Tumor CellsLocal determinationIn effectL38566Palmetto GBAUpdated Jun 24, 2025
- Lab: Bladder/Urothelial Tumor MarkersLocal determinationIn effectL33420Palmetto GBAUpdated Feb 25, 2021
- Screening for Colorectal Cancer-Non-Invasive Biomarker TestsNational analysisReview closedCAG-00440RUpdated Sep 22, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "NMP22 BladderChek", any status and sponsor, newest update first.
No registered device study names "NMP22 BladderChek".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NMP22 BladderChek", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NAH
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NMP22 BladderChek"[tiab]. The summary above synthesizes these.
- Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.
Wang Z, Que H, Suo C, et al. · Oncotarget · 2017
- NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.
Tomera KM · Expert Rev Mol Diagn · 2004Review
- BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH, Meisl CJ, Schlomm T, et al. · Urol Oncol · 2023Multicenter Study
- Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A, Kumar R, Gupta NP · Jpn J Clin Oncol · 2006Comparative Study
- Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM, Kiemeney LA, Witjes JA · Eur Urol · 2005Comparative Study
- Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y, OʼSullivan P, Raman JD, et al. · Urol Oncol · 2017Clinical Trial, Comparative Study
- Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK, Sarungbam J, Bhatia A, et al. · Diagn Cytopathol · 2010
- Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Soorojebally Y, Neuzillet Y, Roumiguié M, et al. · World J Urol · 2023Systematic Review
- [Tumor marker tests in bladder cancer].
Feil G, Stenzl A · Actas Urol Esp · 2006English Abstract, Review
- Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
Lotan Y, Elias K, Svatek RS, et al. · J Urol · 2009Evaluation Study, Research Support, Non-U.S. Gov't
- Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
Tritschler S, Scharf S, Karl A, et al. · Eur Urol · 2007Comparative Study, Validation Study
- [Usefulness of NMP22 BladderChek for the diagnosis and monitoring of bladder cancer].
Seo S, Cho S, Hong K, et al. · Korean J Lab Med · 2007Evaluation Study
Other devices of this type
Also filed under product code NAH.
- Alere NMP22 Bladdercheck Test & Control KitAbbott Diagnostics Scarborough, Inc. · PMA 2012
- Alere NMP22 Urine Collection KitAbbott Diagnostics Scarborough, Inc. · PMA 2012
- NMP22 Elisa Test KitAbbott Diagnostics Scarborough, Inc. · PMA 2008
- Matritech NMP22 Test KitAbbott Diagnostics Scarborough, Inc. · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.